PT1750683E - Formulações de libertação sustida - Google Patents

Formulações de libertação sustida

Info

Publication number
PT1750683E
PT1750683E PT57423154T PT05742315T PT1750683E PT 1750683 E PT1750683 E PT 1750683E PT 57423154 T PT57423154 T PT 57423154T PT 05742315 T PT05742315 T PT 05742315T PT 1750683 E PT1750683 E PT 1750683E
Authority
PT
Portugal
Prior art keywords
sustained release
release formulations
formulations
sustained
release
Prior art date
Application number
PT57423154T
Other languages
English (en)
Portuguese (pt)
Inventor
Merrill S Goldenberg
Jian Hua Gu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT1750683E publication Critical patent/PT1750683E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT57423154T 2004-04-23 2005-04-25 Formulações de libertação sustida PT1750683E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56524704P 2004-04-23 2004-04-23

Publications (1)

Publication Number Publication Date
PT1750683E true PT1750683E (pt) 2013-01-25

Family

ID=34967842

Family Applications (1)

Application Number Title Priority Date Filing Date
PT57423154T PT1750683E (pt) 2004-04-23 2005-04-25 Formulações de libertação sustida

Country Status (15)

Country Link
US (2) US7323169B2 (enExample)
EP (1) EP1750683B1 (enExample)
JP (3) JP5036533B2 (enExample)
KR (1) KR101201638B1 (enExample)
CN (2) CN1997356A (enExample)
AU (1) AU2005237542B2 (enExample)
CA (1) CA2563185C (enExample)
DK (1) DK1750683T3 (enExample)
ES (1) ES2400687T3 (enExample)
IL (1) IL178596A (enExample)
PL (1) PL1750683T3 (enExample)
PT (1) PT1750683E (enExample)
SI (1) SI1750683T1 (enExample)
WO (1) WO2005105057A1 (enExample)
ZA (1) ZA200609401B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323169B2 (en) * 2004-04-23 2008-01-29 Amgen Inc. Sustained release formulations
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
EP1841455A1 (en) 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
EP1904525A4 (en) * 2005-06-30 2009-10-21 Ipsen Pharma GLP-1 PHARMACEUTICAL COMPOSITIONS
WO2007117356A2 (en) * 2006-02-15 2007-10-18 Gammacan Ltd. Immunoglobulins from vitiligo plasma for melanoma therapy
AU2007275638B2 (en) * 2006-07-21 2014-01-16 Amgen Inc. Method of detecting and/ or measuring hepcidin in a sample
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
US20090214654A1 (en) * 2008-02-21 2009-08-27 Isenburg Jason C Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8444624B2 (en) * 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
SG10201601789TA (en) 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
EP2709711B8 (en) 2011-05-18 2017-03-22 Vatrix Medical, Inc. Coated balloons for blood vessel stabilization
JP6145112B2 (ja) 2011-12-19 2017-06-07 アムジエン・インコーポレーテツド 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
AU2015274574B2 (en) 2014-06-10 2019-10-10 Amgen Inc. Apelin polypeptides
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
EP3634507B1 (en) * 2017-06-07 2025-01-15 EGY-Nano Pharma, LP Oral prolonged drug delivery platforms
KR20210080349A (ko) 2018-08-03 2021-06-30 넥테로 메디칼, 인크. 정제된 펜타갈로일 글루코스 및 전달용 장치
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
CN119326891B (zh) * 2024-10-31 2025-07-01 中国人民解放军空军军医大学 Ei24激动剂以及在制备抑制食管鳞癌增殖的制剂的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
GB929406A (en) * 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
CH498653A (fr) * 1968-03-29 1970-11-15 Kobayashi Takehiko Procédé d'encapsulation de matières hydrophobes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
JP2744572B2 (ja) * 1993-02-17 1998-04-28 鐘紡株式会社 ポリフェノール化合物含有皮膚外用剤組成物の変色防止方法
JPH06345668A (ja) * 1993-06-07 1994-12-20 Shibayagi:Kk 感染防御組成物およびその用途
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
AU4414497A (en) 1996-09-13 1998-04-02 University Technology Corporation Biocompatible cationic detergents and uses therefor
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
BR9811478A (pt) * 1997-07-23 2000-08-15 Perio Prod Ltd Composições de polìmero-ácido tânico para a liberação controlada de agentes farmacêuticos particularmente na cavidade oral
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
DE69921636T2 (de) * 1998-04-20 2005-11-03 Genzyme Corp., Cambridge Medikamentöse verabreichung von proteinen aus polymergemischen
JP2000080027A (ja) * 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd 徐放性製剤
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
AU1360901A (en) 1999-11-01 2001-05-14 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
WO2002067966A1 (en) 2001-02-22 2002-09-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
JP5013152B2 (ja) 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
US20040142048A1 (en) * 2002-02-22 2004-07-22 Morre Dorothy M. Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer
US20050271603A1 (en) * 2002-07-26 2005-12-08 Stephanie Krammer Compositions comprising lactoferrin
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
US7323169B2 (en) * 2004-04-23 2008-01-29 Amgen Inc. Sustained release formulations

Also Published As

Publication number Publication date
JP5829870B2 (ja) 2015-12-09
CN103920162A (zh) 2014-07-16
AU2005237542B2 (en) 2009-12-17
JP2007534698A (ja) 2007-11-29
CA2563185C (en) 2010-04-20
JP2012036194A (ja) 2012-02-23
JP5036533B2 (ja) 2012-09-26
WO2005105057A1 (en) 2005-11-10
EP1750683B1 (en) 2013-01-09
SI1750683T1 (sl) 2013-04-30
CA2563185A1 (en) 2005-11-10
EP1750683A1 (en) 2007-02-14
JP2012046520A (ja) 2012-03-08
CN103920162B (zh) 2017-07-11
ZA200609401B (en) 2008-05-28
IL178596A0 (en) 2007-02-11
PL1750683T3 (pl) 2013-05-31
US20050271722A1 (en) 2005-12-08
US7323169B2 (en) 2008-01-29
AU2005237542A1 (en) 2005-11-10
CN1997356A (zh) 2007-07-11
HK1103023A1 (en) 2007-12-14
US7732399B2 (en) 2010-06-08
DK1750683T3 (da) 2013-04-15
ES2400687T3 (es) 2013-04-11
HK1200092A1 (en) 2015-07-31
KR20070026457A (ko) 2007-03-08
KR101201638B1 (ko) 2012-11-15
IL178596A (en) 2012-06-28
US20070292506A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
IL184460A0 (en) Sustained release pharmaeutical formulations
IL178596A0 (en) Sustained release formulations
GB2424581B (en) Formulations
IL181265A0 (en) Stabilizing formulations
GB0406819D0 (en) Controlled release compositions
IL188964A0 (en) Sustained drug release composition
EP1765385A4 (en) IMPORTS COMPOSITION WITH DELAYED RELEASE
IL185773A0 (en) Formulations
PL2402005T3 (pl) Formulacje nalbufiny o przedłużonym uwalnianiu
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
EP1951693A4 (en) SOLID FORMULATIONS
IL177328A0 (en) Controlled release formulations
GB0406048D0 (en) Drug formulations
IL179208A0 (en) Intereferon formulations
GB0417248D0 (en) Formulations
GB0417226D0 (en) Formulations
GB0420817D0 (en) Novel formulations
GB0426292D0 (en) Novel formulations
GB0426293D0 (en) Novel formulations
GB0426296D0 (en) Novel formulations
GB0420821D0 (en) Novel formulations
GB0420818D0 (en) Novel formulations
GB0426295D0 (en) Novel formulations
GB0427244D0 (en) Novel formulations